🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Rockwell Medical, Inc. RMTI PHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.rockwellmed.com
Company Profile ↓
$8.06
-23.24% 1Y
Mkt Cap$32.49M
P/E-6.11
P/B0.91
52W High$18.30
52W Low$5.19
Book Value$8.83
EPS (TTM)$-1.32

Company Overview

Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. In addition, it offers dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. The company was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.40.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $69.26M (-31.8% YoY); net profit $-5.31M.
  • Trailing 12 Months Year-on-year growth — revenue +10.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 1.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:1.48%
1 Year:10.60%

Stock Price Performance

1 Year:-23.24%
6 Months:-10.44%
3 Months:+22.12%
1 Month:+12.89%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 22% of range
$5.19 $18.30
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)60.19 · Neutral
Price Performance
1M+12.89%
3M+22.12%
6M-10.44%
1Y-23.24%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.

CONS

  • Trading 56.0% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-6.11
Industry PE
24.83
Forward P/E
115.14
PEG Ratio
4.43
Book Value
$8.83
Price to Book
0.91
P/S
0.47
EV/EBITDA
-8.91
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
1.48%
Profit 5Y
-
Revenue (YoY)
10.60%
Earnings (YoY)
-

Profitability & Returns

ROCE
-9.86%
ROE
-15.53%
ROA
-5.18%
Profit Margin
-7.33%
Op Margin
-5.97%
Gross Margin
17.71%
EPS (Latest Qtr)
$-0.40
EPS (TTM)
$-1.32

Balance Sheet & Liquidity

Debt/Equity
0.40
Quick Ratio
2.96
Current Ratio
3.25
Debt
$13.93M
Total Assets
$57.42M
Current Assets
$36.94M
Working Capital
$28.58M

Ownership

Promoter Holding
14.80%
Chg in Prom Hold
-0.31%
FII / Inst Holding
8.52%
Chg in FII Hold
-1.00%

Financial Snapshot

Enterprise Value
$32.49M
Total Revenue (TTM)
$69.39M
EBITDA
$-2.43M
Free Cash Flow
$350.38K
Operating Cash Flow
$2.90M
Shares Outstanding
4.03M
Gross Margin
17.71%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 RMTI Rockwell Medical, Inc. PHARMA 8.06 -6.11 $32.49M 0.00% -9.86% -15.53% 1.48% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ---------14.59M13.24M14.63M-14.95M14.91M16.67M15.56M14.85M15.41M15.86M15.90M15.28M15.47M15.14M15.99M16.12M18.68M18.69M19.67M18.08M23.77M22.68M25.83M28.32M-18.91M16.07M15.93M18.35M17.34M
Cost of Revenue -----------------------------------15.87M13.57M13.65M14.47M14.44M
Gross Profit 2.58M2.31M2.07M2.50M2.06M1.69M1.49M1.58M1.99M2.36M1.50M1.07M-1.22M-720.49K-4.02M1.97M1.01M733.15K-17.00K1.11M881.00K346.00K401.00K-262.00K-329.00K-786.00K1.75M777.00K2.60M1.03M2.20M3.06M4.55M6.24M-3.04M2.50M2.27M3.88M2.90M
Operating Expenses -----------------------------------4.40M3.85M3.86M4.28M4.38M
Operating Income -5.02M-3.81M-2.65M-2.57M-6.06M-4.61M-5.59M-4.75M-5.26M-4.96M-6.72M-5.03M-9.22M-5.72M-12.30M-5.00M-8.81M-10.37M-7.94M-8.05M-5.60M-6.69M-7.18M-7.82M-6.97M-6.63M-4.48M-3.71M-1.43M-2.96M-1.74M-1.32M515.00K1.94M--1.36M-1.35M-1.58M-398.00K-1.48M
EBITDA ------------------------------------699.00K-653.00K-924.00K278.00K-812.00K
Interest Expense -----------------------------------277.00K276.00K285.00K286.00K282.00K
Pretax Income ------------------------------------1.51M-1.49M-1.75M-554.00K-1.60M
Tax Provision ----------------------------------------
Net Income -6.38M-3.70M-2.54M-2.41M-5.77M-4.82M-5.36M-4.56M-5.05M-4.74M-7.08M-5.06M-9.04M-5.55M-12.23M-4.97M-8.68M-10.29M-7.86M-7.98M-6.89M-7.35M-7.75M-8.40M-7.58M-7.16M-4.97M-4.19M-1.75M-3.31M-1.87M-1.73M343.00K1.66M--1.51M-1.49M-1.75M-554.00K-1.60M
Diluted EPS --0.07-0.05-0.05--0.10-0.11-0.09--0.09-0.14-0.10--0.13------0.12-0.10-0.10-0.91-0.99-0.89-0.84-0.43-0.23-0.10-0.18-0.07-0.060.010.04--0.40-0.50-0.50-0.10-0.40
R&D Expense 1.68M799.59K885.26K1.25M2.03M1.31M2.06M1.26M1.20M1.21M1.68M1.30M2.13M1.67M1.56M808.19K497.28K2.96M1.48M1.82M1.62M1.75M1.81M2.42M1.22M1.57M926.00K469.00K278.00K167.00K494.00K18.00K00-000--

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 54.73M59.55M48.97M49.84M52.38M54.19M55.35M53.28M57.30M63.39M61.30M62.20M61.93M72.81M83.61M101.49M69.26M
Cost of Revenue -------------68.73M74.91M84.00M57.56M
Gross Profit 7.89M9.86M5.64M6.69M6.66M8.55M8.94M6.75M3.70M-1.58M2.84M2.73M-2.42M4.08M8.70M17.48M11.70M
Operating Expenses -------------20.86M15.37M16.88M16.39M
Operating Income -5.48M-2.87M-21.68M-54.26M-47.06M-17.56M-15.10M-20.21M-25.92M-32.44M-34.52M-28.42M-30.34M-16.78M-6.67M608.00K-4.69M
EBITDA --------------16.17M-4.69M2.95M-2.00M
Interest Expense -------------1.94M2.30M1.25M1.12M
Pretax Income --------------18.68M-8.44M-480.00K-5.31M
Tax Provision -----------------
Net Income -5.50M-2.68M-21.44M-54.02M-48.78M-21.33M-14.42M-19.80M-25.92M-32.13M-34.13M-30.89M-32.67M-18.68M-8.44M-480.00K-5.31M
Diluted EPS ------0.52-0.29-0.39-0.51---0.41-3.83-18.90-3.70-0.30-1.50
R&D Expense 6.45M3.42M17.81M48.27M39.38M7.78M4.96M5.84M6.32M5.64M----1.11M19.00K0

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --36.97M31.94M17.03M36.36M98.00M87.82M83.15M58.78M52.56M44.32M77.75M-46.63M52.17M59.21M57.15M
Current Assets --------------35.31M28.77M37.03M38.16M
Cash & Equivalents 5.60M23.04M12.26M5.72M4.71M11.88M65.80M31.20M17.18M8.41M22.71M11.79M48.68M-10.10M8.98M15.66M10.71M
Inventory --------------5.81M5.87M5.78M3.42M
Receivables --------------6.26M10.90M8.29M8.14M
Total Liabilities ---------25.87M25.28M24.00M43.58M-32.53M30.88M26.62M20.16M
Current Liabilities --6.42M13.69M26.99M17.85M9.80M8.09M10.15M9.14M13.20M12.37M12.79M-17.69M16.64M14.09M9.58M
Long Term Debt -----17.92M-----020.95M-7.55M8.29M8.47M8.83M
Total Debt --------------16.36M13.44M13.54M12.47M
Total Equity 11.82M29.32M30.54M18.24M-9.96M595.54K68.70M62.32M52.96M32.91M27.28M20.32M34.17M-14.11M21.29M32.59M36.98M
Shares Outstanding --------------1.22M2.91M3.41M3.94M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -1.43M2.10M-10.78M-30.75M-50.66M4.26M-13.33M-12.45M-21.11M-20.42M-27.25M-29.64M--16.93M-9.41M4.20M-659.00K
Investing Cash Flow -1.60M-12.92M-587.93K11.52M-12.65M-8.81M-21.14M-1.64M14.50M12.72M-4.75M3.21M--2.40M-3.04M-4.87M-8.54M
Financing Cash Flow 20.47M46.73K4.82M18.22M70.48M58.47M-132.67K80.16K-2.16M22.00M21.09M63.32M-16.15M11.34M7.35M4.25M
Capital Expenditure --------------281.00K-284.00K-1.01M-542.00K
Free Cash Flow --------------17.21M-9.70M3.19M-1.20M
Net Change in Cash --------------3.17M-1.11M6.68M-4.95M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 14.4%16.6%11.5%13.4%12.7%15.8%16.1%12.7%6.5%-2.5%4.6%4.4%-3.9%5.6%10.4%17.2%16.9%
Operating Margin % -10.0%-4.8%-44.3%-108.9%-89.8%-32.4%-27.3%-37.9%-45.2%-51.2%-56.3%-45.7%-49.0%-23.0%-8.0%0.6%-6.8%
Net Margin % -10.1%-4.5%-43.8%-108.4%-93.1%-39.4%-26.1%-37.2%-45.2%-50.7%-55.7%-49.7%-52.8%-25.7%-10.1%-0.5%-7.7%
ROE % -18.8%-8.8%-117.5%542.3%-8,191.5%-31.0%-23.1%-37.4%-78.8%-117.8%-168.0%-90.4%--132.4%-39.6%-1.5%-14.4%
ROCE % --9.4%-118.8%544.7%-254.2%-19.9%-18.9%-27.7%-52.2%-82.4%-108.1%-43.8%--58.0%-18.8%1.3%-9.9%

Shareholding Pattern

Insiders
14.80%
Institutions
8.52%
Public Float
10.00%

Top Institutional Holders

#Holder% HeldSharesValue
1 Vanguard Capital Management LLC 3.05% 122.99K $991.91K
2 Geode Capital Management, LLC 0.90% 36.41K $293.61K
3 Renaissance Technologies, LLC 0.89% 35.97K $290.07K
4 Jane Street Group, LLC 0.61% 24.52K $197.78K
5 Vanguard Fiduciary Trust Co 0.58% 23.27K $187.64K
6 Harbour Investments, Inc. 0.54% 21.86K $176.34K
7 Wealthspire Advisors, LLC 0.38% 15.18K $122.46K
8 Blackrock Inc. 0.36% 14.48K $116.75K
9 State Street Corporation 0.25% 10.09K $81.38K
10 Northern Trust Corporation 0.23% 9.19K $74.08K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RMTI

Google News Mon, 07 Sep 2026

Rockwell Medical (RMTI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Eastern Progress

<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxPekNZaDEyVVpiVDU1U3YyQUxzVVJZWTE2LVF4ckR4ek1HVzZOS3JFS0xHTXB0VWcxdXhnQTlTWEdla0hRS3lRcy0yRGg5a090dHplVzFvcHFST0VSUVM3V25xZ2xjT2JrU1FWWk9sRUFjMjBZRGlnZU5IY0FaT1pTYTU1blpXWXMyLWNPQz…

Google News Fri, 27 Mar 2026

Should Value Investors Buy Rockwell Medical (RMTI) Stock? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOdmdHRXdyYjZPWVZQZmJlUWNpTGNOMHU0RHhQMWpqajlJSzBOcHl6NFV3TVpkTUpSMzZad3VLSmFZQXJ2V2YtbzJCZkhmSGJ5OXBnSFQ3RVk5UHJPbFZETVJwZFVMY1lYWTR2ZW5BS19tdkQxbnI5eU43WWlvU0tVb1lFSEVEZ1U4dWthdT…

Google News Mon, 07 Sep 2026

Behavioral Patterns of RMTI and Institutional Flows - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNUk0wQlRyVXpkcnVCblhaTW9CSTlGdzF5TlRQUl9meUdXbWNSSktKaHhmaEZZV0NnNGZsS0xtclVnN0FjVDJRYXNycGl2QTZLMmZ4aTRaYVRaYUtCby1OOTRlSlEwOFhzT0lvenBYajFvM1NBaWM0Yno4NF9ieVNpMEFUbVNqczNod3Vuaj…

Google News Fri, 04 Sep 2026

Rockwell Medical Inc (NASDAQ: RMTI) Share Price, RMTI Stock News, RMTI Share Price & Updates - kalkine.com.au

<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE9wUS10bjBLN0FRWmlRUk9fX0plQlMtb1Zra1NUSExUYnRjSHFUdzhJTGUzcGJrbDhRbFRSLTJzT1VPTzNQbkU5Tm1NQTRUVUs0SmpXTlBn?oc=5" target="_blank">Rockwell Medical Inc (NASDAQ: RMTI) Share Price, RM…

Google News Mon, 29 Jun 2026

Rockwell Medical Announces First Reverse Stock Split In 4 Years – Nasdaq Compliance In Focus As Shares Haven’t Traded Above $1 Since March - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQNEJSYksyUzJ1Vm1FU1U0d1h5V1ZXeDk2Y2Uwc0tGNlN2bE5KRDdVVnE5SUhQSmJLbXpMdmswb3RiNWppMV9xUWtWODR0a3JNRWJLSlA2ZzM1RTVGVWRieXZvTTZYVFh5V2ZVRkhHbzQxOEN4VVFqNjVnLVRvemlQQjJQZUJnTUFLTGltNG…

Google News Mon, 20 Jul 2026

Rockwell Medical Shares Maintain $1 Bid, Nasdaq Matter Closed - Stock Titan

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNandvZzNSMmZudHJlU2tSbFJQMl82RnYwX1huZV9rMUt0TmJSc25nendVQVFHTjZTeHlGbE51ZnpiVFUzNEptSFJscGM2NlFmdXhWWngzVXg4RXlybVdjNWZueElSRHVhUFQ0VXdLOW9SWmpNZGc1WHg5b0pMQlFPYVZ4NUd1My1ZTkFkcD…

RMTI — Frequently Asked Questions

What is the current share price of Rockwell Medical, Inc. (RMTI)?

As of 2026-09-19 21:16 PDT, Rockwell Medical, Inc. (RMTI) trades at $8.06 on NasdaqCM. Its 52-week range is $5.19 to $18.30.

What is the market capitalisation of RMTI?

Rockwell Medical, Inc. (RMTI) has a market capitalisation of $32.49M on NasdaqCM.

What is the P/E ratio of RMTI?

RMTI trades at a trailing price-to-earnings (P/E) ratio of -6.11. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.91.

What is the return on equity (ROE) of RMTI?

RMTI has a return on equity (ROE) of -15.53%. Its return on capital employed (ROCE) is -9.86%.

Is RMTI a good stock to buy?

This page provides a data-driven analysis of Rockwell Medical, Inc. (RMTI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space